Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX – Free Report) from a sell rating to a hold rating in a research report released on Saturday.

EPRX has been the topic of a number of other research reports. Lifesci Capital upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. Leede Financial raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, October 29th. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Eupraxia Pharmaceuticals in a report on Wednesday, August 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $11.67.

Get Our Latest Stock Report on EPRX

Eupraxia Pharmaceuticals Stock Down 1.8%

Shares of NASDAQ:EPRX opened at $6.16 on Friday. The firm has a market cap of $221.52 million, a P/E ratio of -7.08 and a beta of 1.38. Eupraxia Pharmaceuticals has a 12-month low of $2.68 and a 12-month high of $7.19. The business has a fifty day simple moving average of $5.99 and a 200 day simple moving average of $5.46.

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.04. As a group, equities research analysts expect that Eupraxia Pharmaceuticals will post -0.67 EPS for the current year.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE grew its stake in shares of Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after buying an additional 10,059 shares during the period. Quadrature Capital Ltd bought a new position in Eupraxia Pharmaceuticals in the second quarter worth approximately $61,000. TCI Wealth Advisors Inc. acquired a new stake in Eupraxia Pharmaceuticals in the third quarter valued at approximately $65,000. Integrated Wealth Concepts LLC bought a new stake in shares of Eupraxia Pharmaceuticals during the third quarter valued at approximately $71,000. Finally, JPMorgan Chase & Co. raised its position in shares of Eupraxia Pharmaceuticals by 593.2% during the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock worth $108,000 after purchasing an additional 16,017 shares during the period.

Eupraxia Pharmaceuticals Company Profile

(Get Free Report)

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.

Further Reading